🫁 Lung/Head and Neck — 2026-W39

What this page is. Every paper the week's monitor reviewed — including the ones that did not go into the digest. Material marked “Not selected” was reviewed and deliberately left out. It has not been fact-checked to digest standard and is not endorsed. For the curated read, see the digest itself.

Phase 3 RCT in relapsed extensive-stage SCLC after platinum-based therapy, published in NEJM. New antibody-drug conjugate significantly improved overall and progression-free survival versus topotecan, supporting a new second-line standard option.

Long-term exploratory overall survival update (8-year follow-up) from the phase 3 ADAURA trial in resected EGFR-mutant stage IB-IIIA NSCLC, published in J Thorac Oncol. Confirms durable overall survival benefit with adjuvant osimertinib, reinforcing its role as standard adjuvant therapy in this population.

Narrative review of EGFR PACC mutations and exon 20 insertions in NSCLC, published in JCO. Summarizes evolving targeted therapy options and sequencing strategies, informing treatment selection for these historically undertreated EGFR subsets.

News summary in Cancer Discovery of multiple phase III trials in advanced NSCLC presented at the World Conference on Lung Cancer, covering amivantamab and zipalertinib combinations in EGFR exon 20-mutant disease and ivonescimab versus pembrolizumab in PD-L1-positive disease. Highlights emerging first-line treatment options that could reshape standard-of-care discussions pending further data.

Phase 1 dose-escalation trial of the novel dual-state KRAS G12D inhibitor GFH375 in heavily pretreated pancreatic, lung, and colorectal cancers with KRASG12D mutations, published in Nature Medicine. Establishes tolerability and a recommended phase 2 dose, supporting further development of this new targeted approach for a historically undruggable mutation.

Bayesian meta-analysis of phase 3 RCTs in recurrent/metastatic HNSCC with PD-L1 CPS <1, published in JAMA Oncology. Quantifies the uncertain survival benefit of checkpoint inhibitors in this low-PD-L1 subgroup, directly informing treatment selection in this population.

Phase 1b/2 single-arm study of first-line amivantamab plus pembrolizumab in previously untreated PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma, published in Clin Cancer Res. Reports notable response rates with a novel EGFR-MET bispecific/immunotherapy combination, signaling a promising new frontline approach pending randomized confirmation.

Final biomarker and efficacy analysis from a phase 2 study of lorlatinib in ALK-positive NSCLC, published in Journal of Thoracic Oncology, identifying ALK fusion variants and TP53 co-mutations that correlate with survival outcomes and resistance, informing patient selection and monitoring strategies.

Biomarker analysis from the phase II SAVANNAH trial in EGFR-mutant NSCLC progressing on osimertinib, published in Clinical Cancer Research, defining optimal MET IHC/FISH cutoffs to select patients for savolitinib plus osimertinib. Establishes the diagnostic thresholds used to identify patients most likely to respond, directly informing treatment selection in MET-driven resistance.

Whole-genome and transcriptomic profiling study of invasive non-mucinous lung adenocarcinoma stratified by IASLC grade, published in Lung Cancer. Characterizes molecular drivers of higher-grade, more aggressive tumors but does not link findings to a specific therapeutic decision.

Translational genomic/transcriptomic profiling study of relapsed versus treatment-naive small cell lung cancer, published in Journal of Thoracic Oncology. Characterizes resistance-associated mutational signatures, MYC-family amplifications, and immune evasion mechanisms that may inform future therapeutic targets but does not yet link a marker to a specific treatment decision with clinical outcome data.

Single-arm, nonrandomized phase 2 trial of an HPV16-targeted immunotherapy plus pembrolizumab in recurrent/metastatic HPV16-positive head and neck cancer, published in JAMA Oncology. Suggests potential added benefit in both checkpoint-naive and checkpoint-resistant patients but requires randomized confirmation before changing practice.

Retrospective translational study in J Immunother Cancer developing and externally validating a deep-learning CT model to predict immune checkpoint inhibitor-induced pneumonitis risk in NSCLC patients before treatment starts. Could help identify high-risk patients for closer monitoring, but doesn't yet inform a specific drug choice or show clinical outcome validation tied to therapy selection.

Large real-world multimodal AI study in NSCLC patients receiving immunotherapy, published in Nature Medicine. An explainable AI tool integrating clinical, imaging, and pathology data outperformed standard clinical scores and improved physician treatment predictions, suggesting future utility for immunotherapy selection.

Translational study in Journal of Thoracic Oncology integrating genomic and transcriptomic profiling in resected EGFR-mutant lung adenocarcinoma to build a multi-omic recurrence risk model validated across multiple cohorts. Could help refine which patients truly benefit from adjuvant osimertinib beyond pathological stage alone.

News report in Cancer Discovery summarizing phase 3 trial data presented at WCLC showing anti-B7-H3 antibody-drug conjugates improved survival over topotecan in relapsed small-cell lung cancer, plus early data on a bispecific/ADC combination. Signals a potential new treatment class for relapsed SCLC once full trial publications emerge.

Retrospective nationwide registry study in advanced NSCLC patients without clinically known driver alterations, published in Lung Cancer. Comprehensive genomic profiling uncovered additional actionable drivers that, when matched to targeted therapy, were associated with improved overall survival, supporting broader use of CGP in driver-negative NSCLC.

Translational study in Cancer Cell using patient biospecimens and clinical trial data to show γδ T cell infiltration predicts response to anti-PD-L1 therapy in small cell lung cancer, and preclinical models show these cells can be harnessed with tarlatamab or zoledronate. Suggests a potential biomarker and combination strategy to enhance immunotherapy responses in SCLC.

Single-center retrospective, propensity-matched comparison of surgical resection versus definitive chemoradiotherapy in locoregional small cell lung cancer, published in Lung Cancer. Suggests a survival benefit for surgery in selected multimodality-treated patients, potentially informing selection for surgical intervention in early-stage SCLC.

Retrospective multicenter cohort study with in silico modeling in Lung Cancer (Q2) quantifying how radiologist disagreement on mesothelioma response assessment (mRECIST) degrades statistical power and endpoint accuracy in clinical trials. Highlights a methodological concern for interpreting and designing mesothelioma trials rather than a direct treatment change.

Preclinical/translational study in Cancer Cell exploring a TET2-driven myeloid reprogramming mechanism to enhance radiotherapy-immunotherapy efficacy, with correlative data from advanced lung cancer patients. Suggests a potential strategy to overcome radiation-induced immunosuppression but remains largely mechanistic/mouse-model based.

Large retrospective SEER-Medicare cohort study in Lancet Oncology examining the association between long-term wildfire-related PM2.5 exposure and overall survival in older lung cancer patients. Highlights an environmental prognostic factor but has no direct implication for systemic therapy selection or treatment decisions.

Translational analysis in Clinical Cancer Research using spatial profiling of resected NSCLC/lymph node tissue after neoadjuvant chemoimmunotherapy to identify immune subtypes and a prognostic gene signature. Proposes a framework for future biomarker-guided treatment selection, pending prospective validation.